Drug General Information
Drug ID	D0S1XO
Former ID	DIB002185
Drug Name	BIBX-79
Drug Type	Small molecular drug
Indication	Arteriosclerosis [ICD9: 440; ICD10:I70]		Terminated	[534217]
Company	Boehringer Ingelheim Corp
Structure		Download 2D MOL 3D MOL
Formula	C23H29ClN2O
Canonical SMILES	C(=O)(N([C@@H]1CC[C@@H](c2ccc(CN(C)C)cc2)CC1)C)c1ccc(cc<br />1)Cl
CAS Number	CAS 175033-26-8
PubChem Compound ID	501396
Target and Pathway
Target(s)	Lanosterol synthase	Target Info	Modulator	[526088], [534217]
BioCyc Pathway	Cholesterol biosynthesis II (via 24,25-dihydrolanosterol)
	Cholesterol biosynthesis III (via desmosterol)
	Cholesterol biosynthesis I
	Superpathway of cholesterol biosynthesis
	Lanosterol biosynthesis
KEGG Pathway	Steroid biosynthesis
	Metabolic pathways
	Biosynthesis of antibiotics
PANTHER Pathway	Cholesterol biosynthesis
PathWhiz Pathway	Steroid Biosynthesis
Reactome	Cholesterol biosynthesis
	Activation of gene expression by SREBF (SREBP)
WikiPathways	Activation of Gene Expression by SREBP (SREBF)
	SREBP signalling
	Cholesterol Biosynthesis
	Cholesterol biosynthesis
References
Ref 534217	Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J Lipid Res. 1996 Jan;37(1):148-58.
Ref 526088	Toxicologic lesions associated with two related inhibitors of oxidosqualene cyclase in the dog and mouse. Toxicol Pathol. 2001 Mar-Apr;29(2):174-9.
Ref 534217	Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J Lipid Res. 1996 Jan;37(1):148-58.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.